Leslie Holsinger's most recent trade in Quince Therapeutics Inc was a trade of 10,920 Common Stock done at an average price of $2.9 . Disclosure was reported to the exchange on June 6, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Quince Therapeutics Inc | Leslie Holsinger | EVP, Preclinical Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.86 per share. | 06 Jun 2022 | 10,920 | 148,080 (0%) | 0% | 2.9 | 31,231 | Common Stock |
| Quince Therapeutics Inc | Leslie Holsinger | EVP, Preclinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 155,500 | 159,000 (0%) | 0% | 0 | Common Stock | |
| Quince Therapeutics Inc | Leslie Holsinger | EVP, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 125,000 | 125,000 | - | - | Stock option (right to buy) |